A study by Diallo et al. performed K17 IHC assessment on a TMA in a prospective cohort of 224 breast cancer patients treated with high-dose vs. Dose-dense chemotherapy regimens and found that K17 was a negative predictive factor of OS for patients treated with the dose-dense but not high-dose regimen [69]. This evidence concerns the gene KRT17 and breast cancer.